The latest international news, analysis and features on the HIV epidemic from Avert. Share your views and expertise with your peers in the comments box below the articles.
Researchers recommend dolutegravir (DTG)‐based antiretrovirals should become the first option for HIV treatment in India, following a study into DTG’s cost-effectiveness.
New study provides insights into the factors that influence treatment adherence in Latin America and the Caribbean. Results show that individuals from lower resource settings often achieve higher levels of adherence, contrary to predictions.
Lancet study reveals for the first time who can benefit most from immediate antiretroviral treatment – enabling prioritisation in low-resourced settings. But who is left behind?
Immediate antiretroviral treatment (ART) for people with low CD4 counts in China reduces overall mortality by 63% – confirming trials in other countries that have shown the benefit of early treatment for improved health outcomes.
Agreement ushers in first single-dose, affordable HIV treatment for low- and middle-income countries.
A pilot that saw health workers adopt ‘patient-centred’ communication at an HIV clinic in rural Tanzania led to a three-fold increase in the number of people openly reporting treatment adherence problems.
Long-lasting antiretroviral drugs injected monthly present a ‘remarkable milestone’ in treatment options for people living with HIV
Without urgent action, HIV drug resistance is set to derail the HIV response and presents a significant threat to public health, the World Health Organization (WHO) warns today.
UNITAID partners to bring newer and more effective HIV treatment options to countries where they are needed most.
Key HIV drugs added to the list of medicines critical to public health, including tenofovir for HIV prevention, and dolutegravir.